Clinical Study of Trap (FAPI) 3 PET Imaging in Noninvasive Diagnosis of Malignant Tumors

Launched by DAPING HOSPITAL AND THE RESEARCH INSTITUTE OF SURGERY OF THE THIRD MILITARY MEDICAL UNIVERSITY · Aug 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new type of imaging test called Trap-(FAPI)3 PET, which aims to improve how doctors detect and understand cancer without needing invasive procedures like biopsies. This test uses a special tracer that targets certain cells found in many tumors, helping to highlight cancer more clearly on scans. The goal is to see if this new tracer works better than current methods for finding and staging tumors, which can help guide treatment decisions.

Adults between 18 and 65 years old who have been diagnosed with cancer through biopsy or surgery and may have cancer spread to lymph nodes or other parts of the body could be eligible to participate. Before joining, patients need to agree to the study and meet certain health requirements, such as not having had recent anti-cancer treatments or major surgery. Participants will undergo PET/CT or PET/MR scans using the new tracer to see how well it detects tumors. This study is not yet recruiting, but it offers hope for a safer, more accurate way to diagnose and monitor cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18 and 65 years old, gender is not limited
• • Patients with malignant tumors confirmed by biopsy or surgical pathology
• • Suspected lymph node or distant metastasis found by imaging
• • Written informed consent signed by the subject or his/her legal guardian
• Exclusion Criteria:
• • Patients receiving anti-tumor therapy prior to PET/CT or PET/MR scans
• • Patients with severe medical conditions unable to tolerate PET/CT or PET/MR scans
• • Eligible participants with contraindications for PET/CT or PET/MR scans
• • Participants with radiation exposure exceeding 50 mSv in the past year
• • Participants who underwent major surgery within the last three months or received experimental drugs/instruments (with unclear efficacy/safety) within one month
• • Participants with clinical conditions that the study sponsor considers potentially hazardous or harmful to this investigational agent.